Compare KELYB & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYB | VALN |
|---|---|---|
| Founded | 1946 | 2012 |
| Country | United States | France |
| Employees | 4900 | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.2M | 536.9M |
| IPO Year | N/A | 2021 |
| Metric | KELYB | VALN |
|---|---|---|
| Price | $17.96 | $5.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 2.5K | ★ 31.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.72 | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.38 | $5.06 |
| 52 Week High | $125.00 | $12.25 |
| Indicator | KELYB | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 36.83 |
| Support Level | $11.84 | $5.11 |
| Resistance Level | $18.11 | $6.60 |
| Average True Range (ATR) | 0.98 | 0.25 |
| MACD | -0.19 | -0.05 |
| Stochastic Oscillator | 27.77 | 10.45 |
Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.